ALS LIMITED (ALQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALQ

ALQ - ALS LIMITED

FNArena Sector : Industrial Sector Contractors & Engineers
Year End: March
GICS Industry Group : Commercial & Professional Services
Debt/EBITDA: 2.97
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

ALS Ltd provides laboratory and testing services across the mining, industrial and life sciences sector. It operates in over 65 countries. Formerly Campbell Brothers Ltd it first listed in 1952 and changed name to ALS in 2012.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$21.94

11 Nov
2025

0.000

OPEN

$22.06

0.000

HIGH

$22.35

1,221,826

LOW

$21.73

TARGET
$22.293 1.6% upside
Franking for last dividend paid out: 30%
OTHER COMPANIES IN THE SAME SECTOR
3DA . AVD . BOL . BSA . BWN . CG1 . CLG . CVL . CWY . CXL . DOW . DUR . EGL . FLC . IPG . LBL . MAD . PPK . RWL . SDV . SHA . SND . SSM . SYL . VEE . VNT . VYS .
FNARENA'S MARKET CONSENSUS FORECASTS
ALQ: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 52.9 72.6 xxx
DPS (cps) xxx 38.6 43.6 xxx
EPS Growth xxx 100.0% 37.2% xxx
DPS Growth xxx - 1.5% 13.0% xxx
PE Ratio xxx N/A 30.4 xxx
Dividend Yield xxx N/A 2.0% xxx
Div Pay Ratio(%) xxx 73.0% 60.1% xxx

Dividend yield today if purchased 3 years ago: 3.18%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.75

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 27/11 - ex-div 18.90c (franking 30%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx52.9
DPS All xxxxxxxxxxxxxxx38.6
Sales/Revenue xxxxxxxxxxxxxxx2,999.4 M
Book Value Per Share xxxxxxxxxxxxxxx263.9
Net Operating Cash Flow xxxxxxxxxxxxxxx416.6 M
Net Profit Margin xxxxxxxxxxxxxxx8.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx20.80 %
Return on Invested Capital xxxxxxxxxxxxxxx8.62 %
Return on Assets xxxxxxxxxxxxxxx6.52 %
Return on Equity xxxxxxxxxxxxxxx20.80 %
Return on Total Capital xxxxxxxxxxxxxxx14.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx74.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx164 M
Long Term Debt xxxxxxxxxxxxxxx1,929 M
Total Debt xxxxxxxxxxxxxxx2,093 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx268 M
Price To Book Value xxxxxxxxxxxxxxx5.84

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx165.0 M
Capex % of Sales xxxxxxxxxxxxxxx5.50 %
Cost of Goods Sold xxxxxxxxxxxxxxx2,058 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx471 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx37 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

07/10/2025

1

Buy

$24.60

12.12%

Morgans emphasises junior raisings growth has accelerated in September to record levels, up 260% to US$1.5bn on the prior year. Proprietary raisings data suggests geochemical sample volumes are lifting by circa 20%-30% in November.

September was the fourth consecutive month of raisings over US$1bn, and 12-month trailing raisings are US$11bn, a rise of 72% on the previous period, which is a meaningful indicator for ALS Ltd sample volumes.

The analyst makes no changes to its Life Sciences forecast assumptions but raises Commodities revenue growth estimate in FY26 to 12% from 10%, and up to 20% from 12% in FY27.

Robust operating leverage allows for net profit after tax estimates to rise by 2% in FY26 and between 7%-8% in FY27.

Morgans raises the target price to $24.60 and rates the stock Buy.

FORECAST
Morgans forecasts a full year FY26 dividend of 44.00 cents and EPS of 74.00 cents.
Morgans forecasts a full year FY27 dividend of 55.00 cents and EPS of 91.00 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxx xx xxxxxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

10/11/2025

4

Underweight

$14.85

-32.32%

On November 18, Jarden expects ALS Ltd to report first-half FY26 core profit of $173m, about -1% below the consensus forecast, with investor focus on the FY26-27 outlook, especially for Commodities.

The broker sees Geochemistry volumes improving as gold, copper, and lithium prices rise, while Life Sciences should post solid EBIT growth aided by the Nuvisan turnaround and FX tailwinds.

The share price has already largely re-rated on multiple expansion and offers little room for disappointment, the analysts caution.

Jarden retains an Underweight rating pending clearer evidence of sustained volume and pricing recovery. Target rises to $14.85 from $14.60.

FORECAST
Jarden forecasts a full year FY26 dividend of 43.00 cents and EPS of 72.60 cents.
Jarden forecasts a full year FY27 dividend of 49.60 cents and EPS of 82.70 cents.
Access Extra Coverage Research History >

ALQ STOCK CHART

FNArena News on ALQ

1
Australian Broker Call *Extra* Edition – Nov 10, 2025

Nov 10 2025 - Daily Market Reports
2
Rudi’s View: Amcor, Charter Hall, Challenger, Goodman, Woolworths & More

Nov 06 2025 - Rudi's View
3
Rudi’s View: ALS, Bega, Coles, Elders, Light & Wonder, Lovisa, Telix & More

Oct 23 2025 - Rudi's View
4
Rudi’s View: AI Boom Reveals Our Inner Bias

Oct 01 2025 - Rudi's View
5
Weekly Ratings, Targets, Forecast Changes – 12-09-25

Sep 15 2025 - Weekly Reports

Latest Industrial Sector Contractors & Engineers News

1
Can Ventia Continue to Re-Rate?

Nov 10 2025 - Small Caps
2
Water Megatrend 2.0: Regulations Force Multi-Billion Dollar Investment Boom

Oct 27 2025 - ESG Focus
3
Quenching Growth: How New Desalination Plants Could Boost ASX Stocks

Oct 13 2025 - ESG Focus
4
Introducing ‘Self-Performing’ Contractor Symal

Sep 26 2025 - Small Caps
5
Contractor Duratec’s Secret Sauce

Sep 17 2025 - Small Caps
6
Service Stream’s Positive Defence Surprise

Sep 16 2025 - Small Caps
7
ALS’ Transition Towards More Diversified Future

Jul 09 2025 - Australia
8
Tasmea’s Secret Sauce For Higher-Margin Growth

Jul 07 2025 - Small Caps
9
Southern Cross Electrical Adding Fire As Fuel

Apr 04 2025 - Small Caps
10
Rising Margins Boost ALS’ Favourable Outlook

Nov 22 2024 - Australia